# Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects

> **NCT00447681** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 56 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ILV-094

## Key facts

- **NCT ID:** NCT00447681
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2007-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00447681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00447681, "Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00447681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*